Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
September 01, 2021 08:30 ET
|
Entera Bio Ltd.
‒ Second of Two Presentations to be Delivered by Entera ‒ ‒ Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ‒ BOSTON and JERUSALEM, Sept. 01, 2021 (GLOBE...
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
August 23, 2021 11:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its...
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
August 23, 2021 08:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO...
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
August 16, 2021 06:30 ET
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for...
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
August 13, 2021 16:30 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business...
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
August 02, 2021 08:30 ET
|
Entera Bio Ltd.
‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month...
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
June 28, 2021 15:15 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a...
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
June 23, 2021 08:30 ET
|
Entera Bio Ltd.
Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 monthsSubjects receiving the 2.5 mg dose of EB613 for...
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union
June 17, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Oral delivery technology has potential to transform $20 billion injectable biologics market ‒ ‒ Final BMD results from company’s Phase 2 Osteoporosis study of EB 613 expected in Q2/2021 ‒ ...
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
May 20, 2021 08:00 ET
|
Entera Bio Ltd.
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including...